Fumarate Hydratase Deficient Renal Cell Carcinoma Clinical Trial
Official title:
A Prospective, Single Arm Clinical Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in the First Line Treatment of Patients With Locally Advanced or Metastastic Fumarate Hydratase Deficient Renal Cell Carcinoma
FHRCC is a rare kind of renal cell carcinoma with a morbidity of 1/2000000 per year.Although several combination therapies demonstrated possible efficacy in this population. No standard treatment has been approved. The purpose of this study is to evaluate the efficacy and safety of Lenvatinib in combination with tislelizumab in the first line treatment of patients with locally advanced/metastatic FHRCC.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04068831 -
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03635892 -
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
|
Phase 2 |